PF-04236921

BIOLOGICAL3 trials

Sponsors

Pfizer

Conditions

Crohn's DiseaseHealthyLupus Erythematosus, Systemic

Phase 1

Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers

CompletedNCT01166555

Start: 2010-05-31End: 2010-10-31Updated: 2010-11-23

Phase 2

B0151005 Open-Label Extension Study

CompletedNCT01345318

PfizerCrohn's Disease

Start: 2011-06-30End: 2016-03-31Updated: 2024-01-12

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

CompletedNCT01405196

PfizerLupus Erythematosus, Systemic

Start: 2011-12-31End: 2014-03-31Updated: 2017-12-19

Related Papers

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

Gut2017-12-15174 citations

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

Annals of the Rheumatic Diseases2016-09-27128 citations